Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PRCS -- Ignore unavailable to you. Want to Upgrade?

To: XenaLives who wrote (56)	11/8/2001 1:28:57 PM
From: Harold Engstrom	Respond to of 78

As a shareholder I hope you are right. I think the CEO was also CEO at Immulogic, wasn't he? I was a shareholder there, too, and the lack of organizational follow-through with respect to trial structure spelled disaster for that company. As I recall (and my memory could be faulty here) Immulogic ran 3 PIII trials for its hay-fever vaccine and were told to go back to the drawing board again. I signed on with PRCS because of its high-quality partnerships as well as its pipeline: I thought that Amgen and SS could shepherd drugs through the clinic to market without the same snags that Immulogic fell victim to. Naturally, I am now having flashbacks.